The role of basal metabolic and volumetric 18F-FDG PET/CT 18 parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy

Basit Öğe Kaydı
dc.contributor.authorKepenek, Ferat
dc.contributor.authorKaraoglan, Huseyin
dc.contributor.authorCan, Canan
dc.contributor.authorKomek, Halil
dc.contributor.authorKaplan, Ihsan
dc.contributor.authorEtem, Hulya
dc.contributor.authorEbinc, Senar
dc.date.accessioned2024-04-24T17:45:07Z
dc.date.available2024-04-24T17:45:07Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: The aim of this study is to investigate the roles of pre-and post treatment quantitative fluorine-18-fluorodeoxyglucose ( F-FDG) positron emission tomography/computed tomography (PET/CT) para-18 meters including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) and their rate of change in predicting pathological complete response (pCR) in patients with local and locally advanced invasive breast cancer receiving neoadjuvant chemotherapy (NAC). Subjects and Methods: Ninety-eight patients who received NAC after being diagnosed with local and locally advanced invasive breast cancer between January 2017 and September 2021 were retrospectively included in our study. Molecular subtypes of all patients were determined. Maximum SUV, MTV, TLG, percent change in SUVmax (ASUVmax), AMTV, and ATLG obtained from PET/CT scans performed before and after NAC were calculated. The cut-off, area under curve (AUC), sensitivity, and specificity values of these parameters in predicting pCR were calculated using receiver operating characteristic (ROC) curves. Results: ATMTV (cut-off 94.01%, AUC: 0.846), ATTLG (cut-off 97.36%, AUC: 0.870), B2MTV (cut-off < 1.75, AUC: 0.764), B2TLG (cut-off < 2.11, AUC: 0.764), B2SUVmax (cut-off < 1.58, AUC: 0.767), ABMTV (cut-off 93.67%, AUC: 0.851), ABTLG (cut-off 97.22%, AUC: 0.870), ABSUVmax (cut-off 84.99%, AUC: 0.846) calculated using ROC curves were found to significantly predict pCR with high sensitivity and specificity. Conclusion: We concluded that meta-bolic and volumetric PET/CT parameters, the rates of their change, and metabolic res-ponse during NAC may be important variables in predicting pCR in patients with breast cancer.en_US
dc.identifier.endpage246en_US
dc.identifier.issn1108-1430
dc.identifier.issn1790-5427
dc.identifier.issue3en_US
dc.identifier.pmid36507879
dc.identifier.startpage235en_US
dc.identifier.urihttps://hdl.handle.net/11468/22430
dc.identifier.volume25en_US
dc.identifier.wosWOS:000910900100002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherHellenic Soc Nuclear Medicineen_US
dc.relation.ispartofHellenic Journal of Nuclear Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeoadjuvant Chemotherapyen_US
dc.subjectPathological Complete Responseen_US
dc.subjectF-18-Fdg- Pet/Cten_US
dc.titleThe role of basal metabolic and volumetric 18F-FDG PET/CT 18 parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapyen_US
dc.titleThe role of basal metabolic and volumetric 18F-FDG PET/CT 18 parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu